29th Nov 2018 10:12
LONDON (Alliance News) - Belgium-based diagnostics firm Biocartis Group NV on Thursday unveiled an agreement with AstraZeneca PLC in which the two will work to improve the speed of lung cancer test results.
A prospective lung cancer study with Biocartis's Idylla EGFR Mutation Test will be conducted in Belgium, France, Germany and Italy.
The goal of this is to determine whether Biocartis's Idylla platform can address the complexity and long turnaround time for the biomarker tests that are used to diagnose lung cancer.
"We are very excited to be collaborating with AstraZeneca in the area of lung cancer. With this prospective study, we expect to once again demonstrate the positive impact of delivering highly accurate biomarker results in a fast and easy way, to the benefit of the patients. For Biocartis, this is yet another important collaboration to support the further roll-out of our Idylla platform,2 said Biocartis Chief Executive Herman Verrelst.
Shares in AstraZeneca were up 0.8% at 6,162.00 pence on Thursday.
Related Shares:
Astrazeneca